Clindamycin adjunctive therapy for severe Staphylococcus aureus treatment evaluation (CASSETTE)—an open-labelled pilot randomized controlled trial

BACKGROUND: Combination antibiotic therapy with an antitoxin agent, such as clindamycin, is included in some guidelines for severe, toxin-mediated Staphylococcus aureus infections. The evidence to support this practice is currently limited to in vitro, animal and observational human case-series data...

Descripción completa

Detalles Bibliográficos
Autores principales: Campbell, A. J., Dotel, R., Braddick, M., Britton, P. N., Eisen, D. P., Francis, J. R., Lynar, S., McMullan, B., Meagher, N., Nelson, J., O’Sullivan, M. V. N., Price, D. J., Robinson, J. O., Whelan, A., Tong, S. Y. C., Bowen, A. C., Davis, J. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8884362/
https://www.ncbi.nlm.nih.gov/pubmed/35237755
http://dx.doi.org/10.1093/jacamr/dlac014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8884362/
https://www.ncbi.nlm.nih.gov/pubmed/35237755
http://dx.doi.org/10.1093/jacamr/dlac014

Ejemplares similares